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Abstract
Alendronate belongs to a class of drugs called bisphosphonates. Bisphosphonates (BP) therapy is a vital option to
reduce the risk of bone fracture in people who suffer from osteoporosis. Yet, bisphosphonate have displayed several side
effects. Lepidium sativum (LS) seeds have been used in traditional folk medicine to heal fractured bones. However, there is a
dearth of information on the impact of LS on bone metabolism especially in cases of glucocorticoids induced osteoporosis.
Therefore, the aim of the study was to compare the biochemical bone markers and histological responses of LS alone (6 g of
LS seeds in diet daily, n=8), ALD (alendronate, 70 mg/kg s.c.; n=8) alone, or LS and ALD combined in a rat model of
glucocorticoid-induced osteoporosis (GIO) by injecting rats with methylprednisolone 3.5 mg/kg per day for 4 weeks. Serum
calcium (Ca), albumin, phosphorus (P), bone-specific alkaline phosphatase (b-ALP), and tartrate-resistant acid phosphatase
(TRAP) were measured 4 weeks after induction of GIO. GIO-group showed significantly increased serum TRAP and
decreased b-ALP. GIO-group also showed significantly decreased serum P and unaltered Ca concentrations. Histological
examination of GIO-group tibia bones indicated an osteoporotic change and a concomitant decrease in percentage of
trabecular area or bone marrow area (PTB) in the proximal femoral epiphysis. Treatment with either LS and/or ALD
ameliorated the above mentioned changes with variable degrees, with a net results of enhanced serum calcium, bone
architecture, PTB, b-ALP and decreased TRAP in LS and LS+ALD groups compared to that of animals treated with
alendronate alone. In conclusion, our findings present evidence supporting the potential benefits of LS in reducing the burden
of GCs on bone health.
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Introduction
Osteoporosis is a skeletal disorder in which bone strength is compromised, resulting in an increased risk of fracture
(Giangregorio et al., 2009). Sustaining a hip fracture is one of the most serious consequences of osteoporosis. Nearly one
third of those who sustain osteoporotic hip fractures enter nursing homes within the year following the fracture, and one
person in five dies within one year of experiencing an osteoporotic hip fracture (Rackoff and Rosen 1998).
Glucocorticoids are important in the management of chronic, noninfectious, inflammatory and rheumatic diseases
(Goulding, 2004, Meduri et al., 2002, Ono et al., 2006). Bone loss is one of the most devastating side effects of
glucocorticoids because they inhibit calcium transport, cause secondary hyperparathyroidism, hypogonadism, and
impairment of osteoblast function (Patschan et al., 2001, Rackoff and Rosen 1998). In addition, pre-menopausal women
requiring glucocorticoids are at a significant risk of developing glucocortiocoid-induced osteoporosis (Ledwich and Clarke
2009, Silverman and Lane 2009).
Bone loss can be minimised through proper nutrition, weight-bearing exercise, calcium and vitamin D
supplementation, and, where indicated, bisphosphonate treatment (Garnero 2008, Siris et al., 2009). Bisphosphonate
(alendronate) therapy is a vital option in the prevention and treatment of GIO (de Nijs et al., 2006). However, these agents
have had disappointing results in clinical trials (Hoes et al., 2010, Jacobs et al., 2007). In addition, animal studies with
bisphosphonates have displayed maternal toxicity, foetal underdevelopment, embryo-lethality, hypocalcaemia and skeletal
retardation during pregnancy (Hassen-Zrour et al., 2009, Minsker et al., 1993). Bisphosphonates are therefore contra-
indicated in pregnancy and have an FDA category C pregnancy risk (McNicholl and Heaney 2009). Their use in pre-
menopausal women prior to conception may also pose a teratogenic risk because bisphosphonates remain in mineralised bone
for several years. Consequently, a clinical dilemma exists in treating and preventing GIO in pre-menopausal women.
Herbal medication has been and remains commonly used instead of chemical drugs because of its minor side
effects. Lepidium sativum L. (LS), or what is called locally “hab arachad”, is a native shrub belonging to Brassicaceae family,
wildly grown in the Middle East where LS is largely recommended by traditional herbal healers for hypertension, diabetes
control, renal disease and phytotherapy. The LS seeds are well known in Saudi Arabia and some other Arab countries as a
good alternative medication for fracture healing (Juma, 2007). This property has attracted our interest to study its ability to
treat GIO in rats.
Analysis of Lepidium sativum leaves showed that it consists of water, protein, fat, carbohydrate, mineral matter,
calcium and phosphorus, trace elements: iron nickel cobalt and iodine; vitamins; vitamin A, thiamine, riboflavin, niacin and
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ascorbic acid. Cooked leaves contain vitamin A, thiamine, riboflavin, niacin, and ascorbic acid, moisture, protein, fat, ash,
and sulphur. The seeds contain an alkaloid, glucotropaeloin, sinapin, sinapic acid, mucilaginous matter and uric acid. The oil
contents of saturated and unsaturated acids are palmitic, stearic, arachidic behenic lignoceric, loeic, and linolenic. The
usaponifiable matter contains β-sitosterol and -tocopherol (Gokavi et al., 2004).
Many studies have assessed the influence of L sativum seeds (Juma, 2007) and roots (Zhang et al., 2206; Gonzales,
2012) on bone health. However, there is a dearth of information on the impact of Lepidium sativum on bone metabolism,
especially in cases of glucocorticoids induced osteoporosis. In addition there is an urgent need to find out new modalities
other than bisphosphonates therapy for osteoporosis due to its unsafe side effects. Therefore, we aimed to compare the
biochemical effects of Lepidium sativum and alendronate on glucocorticoid-induced osteoporosis in adult female rats.
Materials and Methods
Experimental Animals
Forty female Wistar rats (40 female rats, weight 100-125 g) were housed in temperature and humidity controlled
conditions and were fed standard rat chow containing 53% vegetable starch, 4.5% fat, 22% protein, 0.36% sodium, and
1.08% potassium prior to experiments. Animals were divided randomly into 5 groups (8 rats/group), and all procedures were
conducted according to the guidelines of the Animal Scientific Procedures Act (United Kingdom, 1986). The animals were
housed in stainless steel cages at room temperature of 27±2°C. All the test and control animals had free access to food and
tap water till the end of the experiment. Control rats were fed with a normal diet, but the test animals had, in addition, 6 g of
L. sativum seeds in their food daily. These seeds were obtained from the local market of the type grown in the Al-Qaseem
area in Saudi Arabia (Juma, 2007). Rats were weighed weekly to detect any change in body weight.
Osteoporosis was induced in rats as previously reported (Hulley et al., 2002). Briefly, all rats except controls were
injected subcutaneously (s.c.) with methylprednisolone 3.5 mg/kg per day for 4 weeks and were divided into the following
groups: (GC) group included rats that were left without treatment to serve as osteoporosis control, (GC+ALD) group included
osteoporotic rats injected subcutaneously with 70 mg/kg body weight of Alendronate (2 injections/week) (Sass et al., 1997),
(GC+LS) group included osteoporotic rats fed 6 g LS seeds in diet daily, GC+ (LS+ALD) group were osteoporotic rats
treated with alendronate and were fed 6g LS seeds in diet daily. Control rats were given a daily subcutaneous injection of
saline (HC). Blood samples were taken from the retro-orbital sinus under light ether anaesthesia after an overnight fast in
heparinzed capillary tubes and blood serum were separated and stored at -20oC until further analysis.
Biochemical Measurements
Blood serum samples were analysed for calcium (Ca), phosphorus (P), albumin (ALB) concentrations using an
automated analyser (Cobas Diagnostic System, Hoffman La Roche Inc., Indianapolis, IN). Serum bone-specific alkaline
phosphatase (b-ALP) concentrations were measured by immunoassay using the Access Ostase Assay (Beckman Access,
Beckman Coulter Inc., Fullerton, CA, USA). Serum tartrate-resistant acid phosphatase (TRAP) concentrations were
measured coloremetrically using commercially available test kit according to manufacturer guidelines (Cayman Chemical,
Ann Arbor, MI, USA). The kit included L-tartrate, an inhibitor of non-tartrate resistant APs.
Measurement of Bone Ash and Ca Content
Each left femur was desiccated in different baths of alcohol and dried overnight at 100◦C. The dry weight was then
determined. Next, the vertebra was incinerated for 12 hours at 1000◦C, and the ash weight was determined. The
measurements obtained were expressed as the percentages of the ash amounts relative to the dry weight of the vertebra. The
ash was then solubilized in 6 N HCl and analysed for Ca content as described previously (Shahnazari et al., 2009). Values
were expressed as milligram of Ca per cubic centimetre of bone volume. Bone volume was measured in the right femur using
Archimedes' principle (Kasra and Grynpas 1995).
Histopathological Examination
The right tibia was dissected from each animal, weighed, fixed in 70% (v/v) ethanol and embedded in paraffin wax
for cross sectioning. Five micron sections were stained with Haematoxylin and Eosin (H&E) and examined under light
microscopy. The trabecular bone tissue of the proximal epiphysis of the femur was photographed at 20X magnification. The
cross-sectional total, bone and marrow areas were measured using ImageJ software (http://rsb.info.nih.gov/ij/), and the
percentage of trabecular area/bone marrow area (PTB) was than calculated.
Statistical Analyses
Results were expressed as mean ± SD. All experimental data were analysed using one-way analysis of variance
with Dunnett’s test. Values of P < .05 were considered statistically significant.




The initial weights and final weights are shown in Table 1. At the beginning and end of the experiment, there was
no difference in weight between controls and GIO rats (p > 0.05). All animals increased their weight during the experiment.
A significant increase in the body weight gain of rats in group received LS (p<0.05) was found compared with GIO group.
Group initial weights(g) final weights(g)
Control rats 270 ± 23 289 ± 31
GIO rats 271 ± 28 280 ± 26
GIO+LS rats 273 ± 16 309 ± 21*
GIO+ALD rats 271 ± 25 291 ± 29
GIO LS+ALD rats 274 ± 17 299 ± 28
Table 1: Initial and final weights in the controls and other groups. Values are means (for 8 rats) with their
standard deviation. * P<0.05 compared with GIO rats.
The mean concentrations of serum Ca in GIO group decreased in comparison to other groups; however, it did not
reach statistical significance (Figure 1A). In contrast, serum phosphorus (P) concentrations were significantly lower in GIO
rats compared with other groups (P<0.0001) (Figure 1B). Treatment with LS significantly raised serum Ca and P levels
(P<0.05).
Effect of LS supplementation on bone metabolic markers revealed a significant increase (P<0.05) in the mean
concentration of serum TRAP, a parameter of bone resorption in GIO-group when compared to HC and treatment groups.
Administration of ALD significantly (P<0.01) decreased serum TRAP. Whereas, no significant difference was found in
TRAP between LS and LS+ALD treated groups (Figure 1C).
The mean concentration of serum b-ALP, a parameter of bone formation, in GIO-group was decreased significantly
(P<0.05) in comparison with untreated HC group. GIO rats showed significant decrease (P<0.05) in b-ALB compared with
HC group. The mean concentration of serum b-ALP was increased significantly in LS-fed and ALD treated groups in
comparison with GIO group (bath at P<0.05). The difference in b-ALP concentrations between group treated with LS alone
and group treated with LS plus ALD was not significant (Figure 1D).
Figure 1: Effects of different treatments on biochemical parameters studied after 4 weeks of osteoporosis induction by
glucocorticoids
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Values are expressed as means ± SD (n=8). *P<0.05; **P<0.01 as compared with GIO.
Effects of methylprednisolone acetate and LS supplementation on histological appearance and trabecular bone
volume of tibia bone were evaluated too. Abnormal histological appearance of the tibia bone was observed in GIO-rats,
where the inner cancellous bone trabeculae lost their normal architecture and appeared as discontinuous bony ossicles
separated by widened bone marrow spaces (Figure 2-b). LS-fed rats revealed marked improvement as compared to those of
the GIO-rats. The cortical bone thickness was very similar to the HC control group. The cancellous bone trabeculae partially
regained near normal structure and appeared more continuous with less widened bone marrow spaces in LS-fed and ALD+LS
groups (Figure 2C, 2D).
Figure 2: Effects of different treatments on the epiphiseal area of the femur A: Osteocytes reside in their lacunae in
between the irregular bone lamellae where bone marrow (BM) spaces are seen between the trabeculae (TB); B: loss
of the normal architecture of trabeculae bone with widening of bone marrow spaces, (C, D) both ALD and LS
treated groups showed denser TB than GIO group, (E) rats treated with both ALD and LS showed the greatest bone
volumes, which appeared to be even greater than that of control group (H&E, 20X).
The trabecular bone volume and percentage of trabecular bone (PTB) were calculated and presented in Figure 3.
PTB was decreased significantly (P< 0.05) in GIO-group in comparison with HC group. On the other hand, the mean PTB
showed a significant increase in LS-group and LS plus ALD groups as compared with the GIO-rat group. In addition, PTB
appeared to be even greater than that of control group; however, the difference did not reach statistical significance (P>0.05).
Discussion
The bone is under constant remodelling, with repeated cycles of bone resorption by osteoclasts followed by
deposition of new bone by osteoblasts. This process ensures the repairing of microfractures as well as remodels the bony
architecture in response to stress (Manolagas, 2000). Osteoporosis occurs when bone resorption exceeds bone formation,
resulting in decreased bone density, degenerated bone microarchitecture and increased risk of fracture (Dempster 2002,
Legrand et al., 2000). Previous studies indicated that GCs induced-osteoporosis occurs as a result of an immediate and
persistent decrease in bone formation and a rapid and transient increase of bone resorption (Dovio et al., 2004).
Bone turnover and bone mineral homeostasis markers have proven useful in screening for fracture risk in elderly
patients, assessing therapeutic response to antiresorptive agents, and identifying patients with high bone turnover to predict
rapid bone loss (Bonnick and Shulman 2006, Garnero 2008). Therefore, the present study was designed to compare the
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efficacy of Alendronate in treating osteoporosis with that of LS in an animal model of GIO by analysing serum markers of
bone remodelling (b-ALP and TRAP) as well as mineral homeostasis markers (Ca and P).
Figure 3: Effects of different treatments on the percentage of trabecular area/bone marrow area (PTB) of the femur Values
are expressed as means ± SD (n=8). *P<0.05; **P<0.01 as compared with GIO.
In vivo studies using short courses of GCs have shown decreased intestinal absorption of calcium (Reid and
Ibbertson, 1987) as well as decreased renal reabsorption of calcium and phosphorus (Cosman et al., 1994, Gram et al., 1998).
Meanwhile, GCs administration was reported to enhance renal calcium excretion by an increased filtered calcium load
secondary to rapidly decreasing bone formation and increasing bone resorption (Schapira et al., 1995). In the present study,
serum Ca concentrations did not show a statistically significant difference between GIO group and control group that might
occur as a result of increased release of Ca from bone tissues. These findings are in agreement with previous studies (Cosman
et al., 1994; Schapira et al., 1995). In addition, our findings of marked decrease in serum P only and not in serum calcium
confirm these data and suggest that the unaltered Ca concentrations, while P levels are decreased, may be caused by a
concomitant net increment of bone resorption releasing more Ca from osteoporotic bones.
GIO-group demonstrated significantly increased concentrations of serum TRAP in comparison with HC-rats.
TRAP is a lysosomal hydrolyser, which has been shown to be released from osteoclasts during bone resorption (Halleen et al.,
2006, Marks and Grolman 1987). This finding suggests an increased bone loss which was supported by the osteoporotic
changes we found by histological examination of tibia bones (Figure 2−B) and a marked decrease in PTB weight (Figure 3). 
In addition, we found a 16% reduction (P<0.05) in serum concentrations of b-ALP in GIO-rats, a marker for bone formation.
Treatment with either LS and/or Alendronate regained the concentration of serum b-ALP to levels higher than that in HC
group (Figure 1D).
It is interesting to note that significant increase in b-ALP concentrations were seen in rats treated with LS and LS
plus Alendronate in comparison with that treated with Alendronate only. The tibia bone weights were also found heavier in
LS and LS+ALD groups compared to that of animals treated with Alendronate alone. These results indicate that LS
suppressed bone resorption in GIO-rats more efficiently than Alendronate alone and may work in a synergistic manner with
Alendronate in lessening bone loss in GIO-rats, as indicated with the augmented serum calcium and b-ALP concentrations
along with enhanced histological structure of tibia bones (Figure 2-E) and increased PTB (Figure 3).
The positive effect on bone density of LS is probably due to its rich content of calcium (Gokavi et al., 2004), and
on its ability to increase serum and liver alpha linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA) (Diwakar et al., 2008), which have been shown to have beneficial effects on bone (Kruger et al., 1998). These results
are in accordance with previously reported benefits of LS seeds that induced a marked influence on fracture healing in rabbits
(Juma 2007). Given the fact that the dose used 2% of LS (w/W) and did not produce any adverse effects or mortality in
animals (Adam 1999), our findings clearly support their use by people at risk of developing osteoporosis, including patients
on GCs therapy and postmenopausal women.
In conclusion, we have demonstrated that co-treatment of ALN and LS, through a short duration (4 weeks), has
significantly improved the biochemical bone indices and restored microarchitecture of femurs and vertebral bones of the GC-
rats compared to ALD and LS single treatment groups. The combined use of LS and ALD may be a new treatment strategy
for preventing bone loss and reversing bone mass and quality in osteoprotic disorders. That deserves further investigations.
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